UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Annals of oncology, 2016-10, Vol.27, p.vi328-vi328

2016

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival After Endoscopic Surgery Versus Radiation as the Initial Treatment in Oropharyngeal Squamous Cell Carcinoma

International journal of radiation oncology, biology, physics, 2016-03, Vol.94 (4), p.892-893

2016

Link zum Volltext

Verfügbarkeit prüfen

HPV-Positive Oropharyngeal Cancer Increased for Both Black and White Patients Over Time, 1992-2007

International journal of radiation oncology, biology, physics, 2014-02, Vol.88 (2), p.494-495

2014

Link zum Volltext

Verfügbarkeit prüfen

Novel Biomarkers Predict Outcome in Patients With HPV-Negative Squamous Cell Carcinoma of the Oropharynx

International journal of radiation oncology, biology, physics, 2014-02, Vol.88 (2), p.524-525

2014

Link zum Volltext

Verfügbarkeit prüfen

Acute Toxicities From Neoadjuvant Compared to Adjuvant Chemoradiation With the Use of Intensity Modulated Radiation Therapy in Resected Pancreatic Cancer Patients

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E172-E173

2015

Link zum Volltext

Verfügbarkeit prüfen

Changes in Lymphocyte-to-Monocyte Ratio During Definitive Chemoradiation Therapy for Locally Advanced Cancers of the Head and Neck Are Prognostic for Survival

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S171-S171

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of Incidental Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Use on Pathologic Complete Response (pCR) to Neoadjuvant Chemoradiation (NA-CRT) in Esophageal Cancer

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E153-E154

2015

Link zum Volltext

Verfügbarkeit prüfen

IMRT Interval and Package Time in Postoperative SCCHN: Does Concurrent Chemotherapy Negate its Importance?

International journal of radiation oncology, biology, physics, 2014-02, Vol.88 (2), p.475-476

2014

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Patients with Oral Cavity Squamous Cell Carcinomas Treated with Adjuvant IMRT with Perineural Invasion

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e569-e570

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy

International journal of radiation oncology, biology, physics, 2024-04, Vol.118 (5), p.e4-e4

2024

Link zum Volltext

Verfügbarkeit prüfen

Outcomes in Patients with Oral Cavity Squamous Cell Carcinomas with Respect to Initiation of Chemotherapy and Adjuvant IMRT Timing

International journal of radiation oncology, biology, physics, 2024-04, Vol.118 (5), p.e22-e22

2024

Link zum Volltext

Verfügbarkeit prüfen

Updated Dose Expansion Results of a Phase 1/1b Study of the Bifunctional EGFR/TGFβ Inhibitor BCA101 with Pembrolizumab in Patients with Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma

International journal of radiation oncology, biology, physics, 2024-04, Vol.118 (5), p.e88-e88

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase 2 Trial of Stereotactic Body Radiation Therapy (SBRT) and Concurrent and Adjuvant Cetuximab vs Cetuximab and Docetaxel in Recurrent, Previously Irradiated Squamous Cell Carcinoma of the Head and Neck

International journal of radiation oncology, biology, physics, 2024-04, Vol.118 (5), p.e43-e44

2024

Link zum Volltext

Verfügbarkeit prüfen

656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma

Annals of oncology, 2022-09, Vol.33, p.S842

2022

Link zum Volltext

Verfügbarkeit prüfen

856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis

Annals of oncology, 2023-10, Vol.34, p.S557-S558

2023

Link zum Volltext

Verfügbarkeit prüfen

922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma

Annals of oncology, 2023-10, Vol.34, p.S582-S583

2023

Link zum Volltext

Verfügbarkeit prüfen

731MO A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S877

2022

Link zum Volltext

Verfügbarkeit prüfen

Increased Utilization of Chemotherapy for Early Stage Oropharyngeal Squamous Cell Carcinoma Despite Evidence for Benefit

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.E360-E360

2017

Link zum Volltext

Verfügbarkeit prüfen

71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results

Annals of oncology, 2020-12, Vol.31, p.S1446-S1447

2020

Link zum Volltext

Verfügbarkeit prüfen

HPV-Positive Oropharyngeal Cancer Increased for Both Black and White Patients Over Time, 1992-2007: Epidemiology and Prevention

International journal of radiation oncology, biology, physics, 2014-02, Vol.88 (2), p.494-495

2014

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

International journal of radiation oncology, biology, physics, 2018-04, Vol.100 (5), p.1307-1307

2018

Link zum Volltext

Verfügbarkeit prüfen

IMRT Interval and Package Time in Postoperative SCCHN: Does Concurrent Chemotherapy Negate its Importance?: Definitive Management of Head-and-Neck Squamous Cell Carcinoma

International journal of radiation oncology, biology, physics, 2014-02, Vol.88 (2), p.475-476

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(7)
Radiology
(7)
Hematology
(1)
Oncology
(1)

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Overall Survival After Endoscopic Surgery Versus Radiation as the Initial Treatment in Oropharyngeal Squamous Cell Carcinoma

HPV-Positive Oropharyngeal Cancer Increased for Both Black and White Patients Over Time, 1992-2007

Novel Biomarkers Predict Outcome in Patients With HPV-Negative Squamous Cell Carcinoma of the Oropharynx

Acute Toxicities From Neoadjuvant Compared to Adjuvant Chemoradiation With the Use of Intensity Modulated Radiation Therapy in Resected Pancreatic Cancer Patients

Changes in Lymphocyte-to-Monocyte Ratio During Definitive Chemoradiation Therapy for Locally Advanced Cancers of the Head and Neck Are Prognostic for Survival

Impact of Incidental Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Use on Pathologic Complete Response (pCR) to Neoadjuvant Chemoradiation (NA-CRT) in Esophageal Cancer

IMRT Interval and Package Time in Postoperative SCCHN: Does Concurrent Chemotherapy Negate its Importance?

Outcomes of Patients with Oral Cavity Squamous Cell Carcinomas Treated with Adjuvant IMRT with Perineural Invasion

A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy

Outcomes in Patients with Oral Cavity Squamous Cell Carcinomas with Respect to Initiation of Chemotherapy and Adjuvant IMRT Timing

Updated Dose Expansion Results of a Phase 1/1b Study of the Bifunctional EGFR/TGFβ Inhibitor BCA101 with Pembrolizumab in Patients with Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma

Randomized Phase 2 Trial of Stereotactic Body Radiation Therapy (SBRT) and Concurrent and Adjuvant Cetuximab vs Cetuximab and Docetaxel in Recurrent, Previously Irradiated Squamous Cell Carcinoma of the Head and Neck

656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma

856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis

922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma

731MO A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors

Increased Utilization of Chemotherapy for Early Stage Oropharyngeal Squamous Cell Carcinoma Despite Evidence for Benefit

71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results

HPV-Positive Oropharyngeal Cancer Increased for Both Black and White Patients Over Time, 1992-2007: Epidemiology and Prevention

A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

IMRT Interval and Package Time in Postoperative SCCHN: Does Concurrent Chemotherapy Negate its Importance?: Definitive Management of Head-and-Neck Squamous Cell Carcinoma

Suchergebnisse filtern